<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4543">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756271</url>
  </required_header>
  <id_info>
    <org_study_id>6738</org_study_id>
    <nct_id>NCT04756271</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of SARS-Cov-2 Inactivated Vaccine</brief_title>
  <official_title>Safety and Immunogenicity of SARS-Cov-2 Inactivated Vaccine in Zagazig University Hospital Health-care Workers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After SARS-COV-2 inactivated vaccine authorization for use in different countries including&#xD;
      Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19&#xD;
      infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by&#xD;
      SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports&#xD;
      regarding the application of vaccine are still limited and deficient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at Zagazig University hospital. Laboratory work will be&#xD;
      implemented at Immunology Research Laboratory at Microbiology and Immunology Department,&#xD;
      Faculty of Medicine, Zagazig University. A representative sample will be drawn from&#xD;
      healthcare workers (HCWs) at Zagazig University Hospital. Assessment of inclusion and&#xD;
      exclusion criteria by history taking. Blood samples will be drawn from HCWs by direct&#xD;
      venipuncture before the start of immunization and 14 days after immunization. The incidence&#xD;
      of any adverse reactions after each immunization will be recorded. SARS-CoV-2 neutralizing&#xD;
      antibodies will be detected by enzyme-linked immunosorbent assay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse reactions</measure>
    <time_frame>7 days after each dose</time_frame>
    <description>Incidence of adverse reactions after each dose of the vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate of neutralizing antibody</measure>
    <time_frame>21 days after each dose</time_frame>
    <description>Neutralizing antibody assay will be performed after each dose of the vaccine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Vaccine Adverse Reaction</condition>
  <condition>Seroconversion</condition>
  <arm_group>
    <arm_group_label>Health-care workers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy health-care workers at Zagazig University Hospital who opt by their free well to administer 2 doses of SARS-Cov-2 inactivated vaccine at 0 and 21 days. Blood samples will be withdrawn from them to investigate the immune response to the given vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-Cov-2 neutralizing antibody titer</intervention_name>
    <description>Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine</description>
    <arm_group_label>Health-care workers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Healthy healthcare workers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy healthcare workers' refusal.&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Confirmed acute cases of SARS-CoV-2 Infection&#xD;
&#xD;
          -  Having a history of SARS-CoV-2 infection in the past 3 months.&#xD;
&#xD;
          -  Fever (body temperature &gt; 37.0 â„ƒ), dry cough, fatigue, nasal obstruction, runny nose,&#xD;
             pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14&#xD;
             days before vaccination.&#xD;
&#xD;
          -  History of allergy to any vaccines&#xD;
&#xD;
          -  Previous vaccination within the last 30 days&#xD;
&#xD;
          -  Immunodeficiency, autoimmune disorders, receiving immunosuppressive therapy or&#xD;
             presence of chronic illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noha M Hammad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Zagazig University , Zagazig, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doaa A Aboalella, MD</last_name>
    <phone>01223512499</phone>
    <email>daaboelelaa@medicine.zu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mai M Malik, MD</last_name>
    <phone>0100071138</phone>
    <email>mmmuhammad@medicine.zu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zagazig University Faculty of Medicine</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha Mohamed El S Hammad</last_name>
      <phone>01224264909</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Noha M Hammad, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

